Leo Antonovich Bockeria

Leo Antonovich Bockeria

Auto-generated profile, based on publicly available information

Leo Antonovich Bockeria

A.N. Bakulev National Medical Research Center of Cardiovascular Surgery

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
LBLeo A. Bockeria
Leo A. Bockeria
OSOleg Svanidze
Oleg Svanidze
AKAlex Kim
Alex Kim
KSKonstantin Shatalov
Konstantin Shatalov
VMVladimir Makarenko
Vladimir Makarenko
TCThierry Carrel
Thierry Carrel

5 March 2013 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
LBLeo Bockeria
Leo Bockeria
VBVladimir Bogin
Vladimir Bogin
OBOlga Bockeria
Olga Bockeria
TLTatyana Le
Tatyana Le
BABagrat Alekyan
Bagrat Alekyan
APAmit N Patel
Amit N Patel
Heart failure is one of the key causes of morbidity and mortality world-wide. The recent findings that regeneration is possible in the heart have made stem cell therapeutics the Holy Grail of modern cardiovascular medicine. The success of cardiac regenerative therapies hinges on the combination of an effective allogeneic “off the shelf” cell product with a practical delivery system. In 2007 Medistem discovered the Endometrial Regenerative Cell (ERC), a new mesenchymal-like stem cell. Medistem and subsequently independent groups have demonstrated that ERC are superior to bone marrow mesenchymal stem cells (MSC), the most widely used stem cell source in development. ERC possess robust expansion capability (one donor can generate 20,000 patients doses), key growth factor production and high levels of angiogenic activity. ERC have been published in the peer reviewed literature to be significantly more effect at treating animal models of heart failure (Hida et al. Stem Cells 2008). Current methods of delivering stem cells into the heart suffer several limitations in addition to poor delivery efficiency. Surgical methods are highly invasive, and the classical catheter based techniques are limited by need for sophisticated cardiac mapping systems and risk of myocardial perforation. Medistem together with Dr. Amit Patel Director of Clinical Regenerative Medicine at University of Utah have developed a novel minimally invasive delivery method that has been demonstrated safe and effective for delivery of stem cells (Tuma et al. J Transl Med 2012). Medistem is evaluating the combination of ERC, together with our retrograde delivery procedure in a 60 heart failure patient, double blind, placebo controlled phase II trial. To date 17 patients have been dosed and preliminary analysis by the Data Safety Monitoring Board has allowed for trial continuation. The combined use of a novel “off the shelf” cell together with a minimally invasive 30 minute delivery method provides a potentially paradigm-shifting approach to cardiac regenerative therapy.

23 February 2011 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
LBLeo A. Bockeria
Leo A. Bockeria
OMOsman A. Makhachev
Osman A. Makhachev
TKTitalav Kh. Khiriev
Titalav Kh. Khiriev
MAMikhail A. Abramyan
Mikhail A. Abramyan
We found 352 cases of congenital unilateral absence of pulmonary artery (UAPA) in the world literature; an additional 67 cases were diagnosed in the Bakoulev Sc

10 April 2013 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
PDF file
LBLeo A. Bockeria
Leo A. Bockeria
SSSergey G. Sukhanov
Sergey G. Sukhanov
EOEkaterina N. Orekhova
Ekaterina N. Orekhova
MSMesrop P. Shatakhyan
Mesrop P. Shatakhyan
DKDmitry A. Korotayev
Dmitry A. Korotayev
LSLeonid Sternik
Leonid Sternik
Background We aimed to evaluate the graft patency rate following coronary artery bypass grafting (CABG) to the left anterior descending artery (LAD) with proximal myocardial bridging (MB). While MB is generally a benign coronary abnormality, ischemia, stunning, and sudden death have been reported. In symptomatic patients with proximal LAD systolic compression of >50%, positive for ischemic noninvasive testing and noneffective optimal medical therapy, coronary intervention could be indicated. Few studies of CABG in myocardial bridging have been reported. The influence of high flow in coronaries with MB on graft patency is cause for concern. Methods We retrospectively studied 39 patients operated on for isolated MB of proximal LAD with >50% systolic compression. All patients were severely symptomatic despite optimal medical therapy and positive noninvasive tests for myocardial ischemia. CABG was performed through the midsternotomy with cardiopulmonary bypass and cardioplegia. Patients were divided into two groups: in 20 patients, LAD was bypassed with left internal mammary artery (LIMA) (Group 1) and in 19 patients with saphenous vein graft (SVG) (Group 2). All patients underwent follow‐up coronary angiography. Results Demographics and degree of systolic compression of the LAD were similar in both groups. There was no mortality or major morbidity. Freedom from angina was 68% in Group 1 and 94% in Group 2 at 18 months postoperatively (p = 0.58). Twelve LIMA grafts and three SVGs were found occluded (p = 0.002). Conclusions LIMA patency in myocardial bridging of the LAD can be low. SVGs should be considered in cases of CABG for myocardial bridging. doi: 10.1111/jocs.12101 (J Card Surg 2013;28:218–221)

1 May 2005 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
VAValery Arakelyan
Valery Arakelyan
ASAlexey Spiridonov
Alexey Spiridonov
LBLeo Bockeria
Leo Bockeria
Operation for aortic recoarctation and/or residual hypoplastic arch represents a surgical challenge because of surrounding scar tissue in the coarctation area, hazard of spinal cord ischemia due to aortic cross-clamping, laceration of the recurrent nerve, and the choice of the best approach. We demonstrate the results of 52 operations of an extra anatomically bypass technique via right thoracotomy approach without establishment of cardiopulmonary bypass. Since 1987, 52 patients underwent extra anatomically positioned ascending-descending bypass grafting. Indication was aortic recoarctation with concomitant hypoplastic aortic arch (45 patients), atypical coarctation of aortic arch (2 patients), congenital anomalies of aortic arch (2 patients) and concomitant aortic coarctation and associated cardiac problems that required surgical repair (2 patient), infected stent-graft of descending aorta (1 patient). Mean age was 19.3 years. Systolic pressure gradients at rest ranged from 35 to 90mmHg; upper extremity hypertension was present in all patients. Operative technique consisted of performing aorta ascending-descending bypass graft size 16 or 18mm in diameter, via right thoracotomy (in 51 patient) or sternotomy (in 1 patient). The mortality rate was 1.9% (1/52). Five patients returned to the operating room (in 3-5 days after operation) for a lymphorrhea complication. An arterial pressure gradient in the limbs was totally corrected. During a follow-up period of actually 79+/-54 months, no adverse event was noticed and antihypertensive medication was stopped in all patients. Ascending-to-descending aortic bypass via right thoracotomy is a safe and effective method for management complex (re-) coarctation and hypoplastic aortic arch.

1 October 2005 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
PDF file
LBLeo Bockeria
Leo Bockeria
EGElena Golukhova
Elena Golukhova
MDMadina Dadasheva
Madina Dadasheva
ARAmiran Revishvili
Amiran Revishvili
ALAlexander Levant
Alexander Levant
TKTea Kakuchaya
Tea Kakuchaya
Objective: To evaluate efficacy of one-step and two-step surgery approach in patients with arrhythmias combined with Ebstein's anomaly. Methods: Fifty-three patients with Ebstein's anomaly combined with tachyarrhythmias (58.5% men, 41.5% women, mean age 21.6±10.7 years) were operated on. In group A (32 patients), one-step surgical correction (simultaneous intraoperative elimination of arrhythmias and congenital heart defect repair) was performed, whereas in group B (21 patients), two-step surgery was performed with initial elimination of arrhythmogenic substrate by transcatheter radiofrequency ablation (first step) and following surgical repair of congenital heart defect (second step). Results: In group A, total hospital mortality was 3.1% (1 patient) due to initial severe condition of this patient. One-step surgery was effective in 93.5% of cases. Mortality was not observed in group B. Efficacy of transcatheter radiofrequency ablation was 76.2%. Conclusions: one-stage and two-stage surgery of arrhythmias and Ebstein's anomaly are highly effective. First step of surgery of combined pathology reduces cardiopulmonary bypass time, complications and mortality while performing the second step of congenital heart defect surgery. However, simultaneous approach (one-step surgery) is better in terms of arrhythmia elimination.